Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) has announced the publication of results from its Phase 2a proof-of-mechanism study evaluating exaluren in patients with nonsense mutation Alport syndrome. The findings have been published in the Journal of Clinical Investigation (JCI) under the title “Phase 2a study of readthrough therapy in nonsense mutation Alport syndrome.”
The study provides early human evidence that genetically targeted readthrough therapy may restore the production of missing proteins in kidney cells and improve cellular structure in a genetic kidney disease.
Phase 2a Study Design
The open-label Phase 2a study (NCT05448755) enrolled three patients aged 12–18 years with autosomal recessive Alport syndrome caused by a premature termination codon in the COL4A4 gene.
Participants received daily subcutaneous exaluren at a dose of 0.75 mg/kg for eight weeks.
The primary endpoint was safety and tolerability, while secondary assessments included kidney biopsy evaluations before and after treatment.
Key Kidney Biopsy Findings
Post-treatment kidney biopsies showed structural and molecular changes in all three participants:
-
Increased abundance of collagen α3(IV), α4(IV) and α5(IV).
-
Physiological localization of collagen α5(IV).
-
Partial improvement in podocyte morphology.
-
Reductions in podocyte foot process width of 46%, 14% and 16%, respectively, based on masked machine-learning analysis of electron microscopy images.
-
Increased filtration slit density in all participants.
Exploratory analysis showed that mean filtration slit density increased by 50%, reaching more than 80% of healthy control values.
However, changes in proteinuria were inconsistent, with interpretation limited by intra-patient variability and the short treatment duration. Haematuria persisted in all participants.
Safety and Tolerability
Exaluren was reported to be well tolerated during the eight-week study. No serious adverse events, treatment discontinuations, nephrotoxicity or ototoxicity were reported, including among adolescents with pre-existing kidney and hearing impairment.
Most adverse events were Grade 1 and resolved spontaneously.
Phase 2b EXACT Trial: Next Development Milestone
Eloxx is evaluating exaluren in the ongoing Phase 2b EXACT study (NCT07523581), a global, randomized, placebo-controlled, delayed-start trial planned to enrol 24 patients with Alport syndrome caused by nonsense mutations in the COL4A3, COL4A4 or COL4A5 genes.
The primary efficacy endpoint during the initial 16-week placebo-controlled period is the change in podocyte foot process effacement, measured through changes in filtration slit density on kidney biopsies. This endpoint applies to non-US paediatric patients and all adult participants.
The first patients were dosed in September 2026. Eloxx expects to report:
-
Mid-2027: Topline results from the 16-week placebo-controlled portion.
-
By the end of 2027: 32-week data.
The company is also planning the Phase 2 EXPRESS study to evaluate exaluren in nonsense mutation autosomal dominant polycystic kidney disease (ADPKD).
About Exaluren and Alport Syndrome
Exaluren, formerly known as ELX-02, is an investigational ribosome-targeting glycoside designed to promote readthrough of premature stop codons while avoiding native stop codons. This approach aims to enable cells to produce full-length, functional proteins.
Alport syndrome is an inherited kidney disease associated with mutations in the COL4A5, COL4A3 or COL4A4 genes, which encode components of the type IV collagen network in the glomerular basement membrane. Nonsense mutations introduce premature stop codons that can prevent the production of full-length collagen IV and are associated with a poor prognosis.
There are currently no approved treatments for Alport syndrome, according to the company.
The Phase 2a findings provide early proof-of-mechanism evidence for exaluren in nonsense mutation Alport syndrome. However, the study involved only three participants and was limited to eight weeks of treatment. Larger controlled studies, including the ongoing EXACT trial, will be needed to determine whether the observed kidney tissue changes translate into meaningful clinical benefits.
Publication: Journal of Clinical Investigation – Phase 2a study of readthrough therapy in nonsense mutation Alport syndrome